All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Syndax, Thermo Fisher Scientific, Kura Oncology, and AbbVie. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.  View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

ASH 2018 | Practice changing abstracts in acute myeloid leukemia 

Jan 1, 1970


Did you miss ASH 2018? The AML Global Portal attended the 60th ASH Annual Meeting & Exposition, December 1–4 2018, San Diego, CA, USA, and has developed a downloadable resource, which provides information on the practice changing abstracts across acute myeloid leukemia (AML).

Our selection of ASH abstracts include comments from the AML Global Portal Steering Committee members on transplantation in AML, venetoclax as new standard of care, IDH1/2 inhibitors, maintenance therapy, MRD status, and the findings of the phase III Quantum-R trial.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content